Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP

Open source

DOI: 10.1016/s1470-2045(23)00452-7
Published: 2023 Dec
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-23-00452-7,
  title = {Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.},
  author = {Niemann CU and Munir T and Moreno C and Owen C and Follows GA and Benjamini O and Janssens A and Levin MD and Robak T and Simkovic M and Voloshin S and Vorobyev V and Yagci M and Ysebaert L and Qi K and Qi Q and Sinet P and Parisi L and Srinivasan S and Schuier N and Baeten K and Howes A and Caces DB and Kater AP},
  year = {2023},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(23)00452-7},
  url = {https://doi.org/10.1016/s1470-2045(23)00452-7}
}

RIS

TY  - JOUR
TI  - Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
AU  - Niemann CU
AU  - Munir T
AU  - Moreno C
AU  - Owen C
AU  - Follows GA
AU  - Benjamini O
AU  - Janssens A
AU  - Levin MD
AU  - Robak T
AU  - Simkovic M
AU  - Voloshin S
AU  - Vorobyev V
AU  - Yagci M
AU  - Ysebaert L
AU  - Qi K
AU  - Qi Q
AU  - Sinet P
AU  - Parisi L
AU  - Srinivasan S
AU  - Schuier N
AU  - Baeten K
AU  - Howes A
AU  - Caces DB
AU  - Kater AP
PY  - 2023
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(23)00452-7
UR  - https://doi.org/10.1016/s1470-2045(23)00452-7
ER  -

APA

CU, N., T, M., C, M., C, O., GA, F., O, B., A, J., MD, L., T, R., M, S., S, V., V, V., M, Y., L, Y., K, Q., Q, Q., P, S., L, P., S, S., N, S., K, B., A, H., DB, C., & AP, K. (2023). Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(23)00452-7

Source records

pubmed · retrieved 2026-09-27T09:29:15.725Z